(Q43795699)

26 November 2017

title

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study (English)

1 reference

26 November 2017

4

1 reference

26 November 2017

6

1 reference

26 November 2017

16

1 reference

26 November 2017

9

Roberto Guariglia

1 reference

26 November 2017

1

Giovanni D'Arena

1 reference

26 November 2017

11

Oreste Villani

1 reference

26 November 2017

Maria Carmen Martorelli

12

object named as

Maria Carmen Martorelli

1 reference

26 November 2017

Giuseppe Pietrantuono

10

object named as

Giuseppe Pietrantuono

1 reference

26 November 2017

13

Giovanna Mansueto

1 reference

26 November 2017

8

Antonietta Falcone

1 reference

26 November 2017

14

Grazia Sanpaolo

1 reference

26 November 2017

Paolo G Gobbi

2

1 reference

26 November 2017

Chiara Broglia

3

1 reference

26 November 2017

Giovanni Quarta

5

1 reference

26 November 2017

Emilio Iannitto

7

1 reference

26 November 2017

Nicola Cascavilla

15

1 reference

26 November 2017

Gimema (Gruppo Italiano Malattie Ematologiche Dell'Adulto)

17

1 reference

26 November 2017

Multiple Myeloma Working Party

18

1 reference

26 November 2017

Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group

19

1 reference

26 November 2017

publication date

8 February 2011

1 reference

26 November 2017

1 reference

26 November 2017

volume

52

1 reference

26 November 2017

issue

5

1 reference

26 November 2017

page(s)

771-775

1 reference

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Therapeutic Options in the Management of Myeloma Bone Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Potential anticancer properties of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.553000

10.3109/10428194.2011.553000

21 January 2018

Identifiers

DOI

1 reference

release_kmio6ioicfbvphd3bz3x6fly6a

26 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kmio6ioicfbvphd3bz3x6fly6a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference